Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
China NT Pharma Group Co., Ltd. ( (HK:1011) ) has provided an update.
China NT Pharma Group Co., Ltd. has announced strategic measures to enhance its business operations and financial stability. The company is focusing on developing a smart health ecosystem in the bone health sector, including testing, treatment, and rehabilitation services, which are expected to become core revenue streams. Additionally, the company has secured agreements with debtors to extend loan terms and has received financial support commitments from major shareholders to aid in its strategic transformation.
The most recent analyst rating on (HK:1011) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.
More about China NT Pharma Group Co., Ltd.
China NT Pharma Group Co., Ltd. operates in the pharmaceutical industry, focusing on transitioning from heavy pharmaceutical assets to new medical and health business models that leverage artificial intelligence. The company aims to develop a full-cycle smart health ecosystem platform, particularly in the bone health field.
Average Trading Volume: 2,117,215
Technical Sentiment Signal: Buy
Current Market Cap: HK$546.1M
Find detailed analytics on 1011 stock on TipRanks’ Stock Analysis page.